Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET

Clinical Nuclear Medicine

Volumn 36, Issue 5, 2011, Pages 331-336

  Lee, Sang Mi ^a   Kim, Tae Sung ^a   Lee, Jeong Won ^b   Kim, Seok Ki ^a   Park, Sang Jae ^a   Han, Sung Sik ^a  

^a National Cancer Center   (South Korea)

^b Jeju National University   (South Korea)

Author keywords

F 18 fluorodeoxyglucose (FDG); Pancreatic cancer; positron emission tomography (PET); prognosis

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; LUNG METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS BIOPSY; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955057983     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31820a9eea     Document Type: Article

References (29)

1. Lee JK. Screening and diagnosis for pancreatic cancer [in Korean]. Korean J Gastroenterol. 2008;51:84-88.
2. Park SJ. Stages and prognostic factors of pancreatic cancer after resection. Korean J Hepatobiliary Pancreat Surg. 2004;8:140-146.
3. Perini M, Montagnini A, Jukemura J, et al. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford). 2008;10: 356-362.
4. Maemura K, Takao S, Shinchi H, et al. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg. 2006;13:435-441. (Pubitemid 44480247)
5. Lyshchik A, Higashi T, Nakamoto Y, et al. Dual-phase 18F-fluoro-2-deoxy- D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur JNucl Med Mol Imaging. 2005;32:389-397. (Pubitemid 40591169)
6. Sperti C, Pasquali C, Chierichetti F, et al. 18-fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003;7:953-959.
7. Diederichs CG, Staib L, Glatting G, et al. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030-1033. (Pubitemid 28270121)
8. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95-101. (Pubitemid 350309328)
9. Pongprasobchai S, Pannala R, Smyrk TC, et al. Long-term survival and prognostic indicators in small (< or = 2 cm) pancreatic cancer. Pancreatol-ogy. 2008;8:587-592.
10. Artinyan A, Soriano PA, Prendergast C, et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008;10: 371-376.
11. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-1585. (Pubitemid 33101907)
12. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359. (Pubitemid 23075371)
13. Fujimoto K, Koizumi S, Nishimura S, et al. Prognostic significance of serum CA19-9 levels in resected pancreatic cancer. HPB (Oxford). 1996;3:66-70. (Pubitemid 126715286)
14. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643-647.
15. Ahmad NA, Lewis JD, Ginsberg GG, et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol. 2001;96:2609-2615.
16. Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer. 1993;72: 2124-2133. (Pubitemid 23280136)
17. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782.
18. Kobari M, Sunamura M, Ohashi O, et al. Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas. J Am Coll Surg. 1996;182:24-32. (Pubitemid 26022134)
19. Park J, Kim S, Kim I, et al. Analysis on recurrence of an invasive ductal adenocarcinoma of the pancreas. Korean J Hepatobiliary Pancreat Surg. 2005;9:171-178.
20. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med. 1993; 34:1-6. (Pubitemid 23014212)
21. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332. (Pubitemid 38552885)
22. Schick V, Franzius C, Beyna T, et al. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging. 2008;35:1775-1785.
23. Wakabayashi H, Nishiyama Y, Otani T, et al. Role of 18F- fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol. 2008;14:64-69. (Pubitemid 351314328)
24. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923-929. (Pubitemid 44690768)
25. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997;38:1344-1348.
26. Greer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68-72.
27. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766-1773. (Pubitemid 40995093)
28. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
29. Hwang YW, Jang HJ, Lee JK, et al. Survival and recurrence pattern after curative resection of pancreatic cancer. Korean J Gastroenterol. 2001;38: 276-283.